<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092416</url>
  </required_header>
  <id_info>
    <org_study_id>ORBIT II</org_study_id>
    <nct_id>NCT01092416</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions</brief_title>
  <acronym>ORBIT II</acronym>
  <official_title>Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Systems Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, multi-center study to evaluate the safety and performance
      of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study
      is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety
      endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects
      will be treated with the orbital atherectomy system and adjunctive stent. All subjects will
      be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call
      or clinical follow up at each anniversary until study is closed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>OAS safety was measured by a composite of MACE at 30-days post procedure. MACE is composed of:
Cardiac death.
MI - defined as a CK-MB level &gt; 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint: Procedural Success</measure>
    <time_frame>Participants were followed from baseline procedure through the duration of hospital stay, an average of 33.6 hours.</time_frame>
    <description>Procedural success was defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>Baseline procedure, with a mean total procedure time of 52.5 minutes.</time_frame>
    <description>Angiographic success was defined as success in facilitating stent delivery with &lt;50% residual stenosis and without severe angiographic complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Angiographic Complications</measure>
    <time_frame>Baseline procedure, with a mean total procedure time of 52.5 minutes.</time_frame>
    <description>Severe angiographic complications were defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Month Freedom From Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>The safety of the OAS was measured for the secondary safety endpoint consisting of a composite of freedom from MACE through 12 months of follow-up.</description>
  </secondary_outcome>
  <enrollment type="Actual">443</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diamondback 360 Orbital Atherectomy System</intervention_name>
    <description>Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 or older.

          -  Subjects must have a clinical indication for coronary intervention.

          -  CK and CK-MB must be less than or equal to the upper limit of lab normal value within
             8 hours prior to the procedure.

          -  The target lesion must be a de novo coronary lesion that has not been previously
             treated with any interventional procedure.

          -  The target vessel must be a native coronary artery with a stenosis of &gt;= 70% and &lt;
             100%.

          -  The target vessel reference diameter must be &gt;= 2.5mm and &lt;= 4.0 mm.

          -  The lesion length must not exceed 40 mm.

          -  The target vessel must have a TIMI flow 3 at baseline.

          -  The target lesion must have evidence of severe calcium deposit at the lesion site
             based on the protocol criterion.

          -  The lesion must be crossable with the study guide wire.

        Exclusion Criteria:

          -  Inability to understand the study or a history of non-compliance with medical advice.

          -  Unwilling or unable to sign the ORBIT II Informed Consent Form (ICF).

          -  History of any cognitive or mental health status that would interfere with study
             participation.

          -  Currently enrolled in any other pre-approval investigational study (does not apply to
             long-term post-market studies unless these studies might clinically interfere with the
             current study endpoints (e.g., limit use of study-required medication, etc.).

          -  Female subjects who are pregnant or planning to become pregnant within the study
             period.

          -  Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or
             clopidogrel without adequate alternative medications.

          -  Known sensitivity to contrast media, which cannot be adequately pre-medicated.

          -  Diagnosed with chronic renal failure or has a serum creatinine level &gt;2.5 mg/dl.

          -  Experienced acute MI (STEMI or non-STEMI: CK and CK-MB greater than 1 times the upper
             limit of lab normal) within 30 days prior to index procedure.

          -  History of major cardiovascular intervention within 30 days.

          -  Evidence of current (within 6 months) left ventricular ejection fraction ≤ 25%.

          -  NYHA class III or IV heart failure.

          -  History of a stroke or transient ischemic attack (TIA) within 6 months.

          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months.

          -  History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion
             if one should become necessary.

          -  Concurrent medical condition with a life expectancy of less than 12 months.

          -  History of immune deficiency.

          -  Uncontrolled insulin dependent diabetes.

          -  Evidence of active infections on the day of the index procedure.

          -  Subject has planned cardiovascular intervention within 60-days post index procedure.

          -  Subject is not an acceptable candidate for emergent coronary artery bypass surgery.

          -  Subject with known allergy to atherectomy lubricant components such as soybean oil,
             egg yolk phospholipids, glycerin and sodium hydroxide.

          -  Subject with 3 lesions requiring intervention.

          -  Subject with 2 lesions unless the treatment of the lesions is staged. The non target
             lesion must first be treated at least 12 hours prior to the index procedure. The
             subject's CK and CK-MB must be less than or equal to one times the upper limit of the
             lab normal value 12 ± 2 hours post procedure and there were no procedural
             complications during the first lesion intervention.

          -  Target lesion is located in a native vessel distal to anastomosis with a saphenous
             vein graft or LIMA/RIMA bypass.

          -  Target vessel has other lesions with greater than 50% diameter stenosis based on
             visual estimate or on-line QCA.

          -  Target vessel has angiographically visible or suspected thrombus.

          -  Target vessel has a stent from previous PCI.

          -  Target vessel is excessively tortuous.

          -  Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left
             main lesion.

          -  Target lesion is a bifurcation.

          -  Target lesion has a ≥ 1.5 mm side branch.

          -  Angiographic evidence of a dissection prior to OAS treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Chambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metropolitan Cardiology Consutants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trinity Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Montgomery South</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Gilbert</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Sinai Los Angeles</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Medical Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Cardiology Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Memorial Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Memorial</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Florida Regional</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Regional</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Gardens</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winter Haven</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Heart Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincents Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's Daughters / Kentucky Heart Foundation</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Research Institute</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland</name>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart &amp; Vascular</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Michaels</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>71878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart and Vascular Center</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr / Lankenau</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Memorial Hospital-DeSoto</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Hospital</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joe Bellingham / North Cascade Cardiology</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Généreux P, Lee AC, Kim CY, Lee M, Shlofmitz R, Moses JW, Stone GW, Chambers JW. Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial). Am J Cardiol. 2015 Jun 15;115(12):1685-90. doi: 10.1016/j.amjcard.2015.03.009. Epub 2015 Mar 24.</citation>
    <PMID>25910525</PMID>
  </results_reference>
  <results_reference>
    <citation>Chambers JW, Feldman RL, Himmelstein SI, Bhatheja R, Villa AE, Strickman NE, Shlofmitz RA, Dulas DD, Arab D, Khanna PK, Lee AC, Ghali MG, Shah RR, Davis TP, Kim CY, Tai Z, Patel KC, Puma JA, Makam P, Bertolet BD, Nseir GY. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). JACC Cardiovasc Interv. 2014 May;7(5):510-8. doi: 10.1016/j.jcin.2014.01.158.</citation>
    <PMID>24852804</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>September 1, 2015</results_first_submitted>
  <results_first_submitted_qc>December 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2016</results_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>Severely calcified lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study received approval to enroll up to 429 subjects. Following the introduction of the Electric OAS, the enrollment was expanded to a maximum of 479 subjects, to enroll 100 subjects with the Electric OAS. A total of 443 subjects were enrolled in the study between May 25, 2010 and November 26, 2012 at 49 U.S. study sites.</recruitment_details>
      <pre_assignment_details>A subject was considered enrolled when a signed informed consent was in place, all inclusion/no exclusion criteria were met, and the study guidewire had crossed the target lesion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ORBIT II Subjects</title>
          <description>Subjects enrolled in ORBIT II study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Atherectomy device not inserted</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>30-Day Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 30-day follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data collected after close of 30D window</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="438"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="413"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 1-year follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data collected after close of 1Y window</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ORBIT II Subjects</title>
          <description>Subjects enrolled in ORBIT II study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="443"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.4" lower_limit="37.4" upper_limit="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE)</title>
        <description>OAS safety was measured by a composite of MACE at 30-days post procedure. MACE is composed of:
Cardiac death.
MI - defined as a CK-MB level &gt; 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.</description>
        <time_frame>30 days</time_frame>
        <population>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>ORBIT II Subjects</title>
            <description>Subjects enrolled in ORBIT II study.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE)</title>
          <description>OAS safety was measured by a composite of MACE at 30-days post procedure. MACE is composed of:
Cardiac death.
MI - defined as a CK-MB level &gt; 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.</description>
          <population>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 30 days.</population>
          <units>Percent probability of Freedom from MACE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="86.7" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Angiographic Success</title>
        <description>Angiographic success was defined as success in facilitating stent delivery with &lt;50% residual stenosis and without severe angiographic complications.</description>
        <time_frame>Baseline procedure, with a mean total procedure time of 52.5 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ORBIT II Subjects</title>
            <description>Subjects enrolled in ORBIT II study</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic Success</title>
          <description>Angiographic success was defined as success in facilitating stent delivery with &lt;50% residual stenosis and without severe angiographic complications.</description>
          <units>Percentage of procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Angiographic Complications</title>
        <description>Severe angiographic complications were defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.</description>
        <time_frame>Baseline procedure, with a mean total procedure time of 52.5 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ORBIT II Subjects</title>
            <description>Subjects enrolled in ORBIT II study</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Angiographic Complications</title>
          <description>Severe angiographic complications were defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type C, D, E, or F Dissection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent Slow Flow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent No Reflow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abrupt Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12-Month Freedom From Major Adverse Cardiac Events (MACE)</title>
        <description>The safety of the OAS was measured for the secondary safety endpoint consisting of a composite of freedom from MACE through 12 months of follow-up.</description>
        <time_frame>12 months</time_frame>
        <population>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>ORBIT II Subjects</title>
            <description>Subjects enrolled in ORBIT II study.</description>
          </group>
        </group_list>
        <measure>
          <title>12-Month Freedom From Major Adverse Cardiac Events (MACE)</title>
          <description>The safety of the OAS was measured for the secondary safety endpoint consisting of a composite of freedom from MACE through 12 months of follow-up.</description>
          <population>A Kaplan-Meier analysis was performed to determine the percent probability that a study participant is free from major adverse cardiac events at 12 months.</population>
          <units>Percent probability of Freedom from MACE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" lower_limit="79.6" upper_limit="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint: Procedural Success</title>
        <description>Procedural success was defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.</description>
        <time_frame>Participants were followed from baseline procedure through the duration of hospital stay, an average of 33.6 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OAS Treatment Group</title>
            <description>Subjects enrolled in ORBIT II study and in whom the atherectomy device was inserted.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint: Procedural Success</title>
          <description>Procedural success was defined as success in facilitating stent delivery with a residual stenosis of &lt;50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.</description>
          <units>Percentage of procedures</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="85.5" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious Adverse Events reported by sites and adjudicated by the Clinical Events Committee.</desc>
      <group_list>
        <group group_id="E1">
          <title>ORBIT II Subjects - 30 Day Results</title>
          <description>Serious Adverse Events reported out to 30 Days Post-Procedure for Subjects enrolled in ORBIT II study.</description>
        </group>
        <group group_id="E2">
          <title>ORBIT II Subjects - 1 Year Results</title>
          <description>Serious Adverse Events reported from 31 Days to 1 Year Post-Procedure for Subjects enrolled in ORBIT II study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute MI, Q-wave</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Acute MI, non Q-wave</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="443"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Atrioventricular block, II degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cardiac/pericardial tamponade</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Non-target vessel revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>PEA arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Shock (Acute RV dysfunction and acute blood loss hypovolemic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia/ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Acute congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Arrhythmia, unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chronic congestive heart failure, or exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Heart flutter/nervous feeling in chest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pacemaker end of life</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral cataracts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Esophageal spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Nausea and/or vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Complicated appendicitis (rupture)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Rectocoele repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Lower extremity pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Supratherapeutic INR</sub_title>
                <description>International Normalized Ratio/Prothrombin time</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Death, unknown cause</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chest pain, non-cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Fall/Loss of balance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Complications post cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Elevated liver function tests</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gallstone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gangrenous gallbladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection at access site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Left arm AV graft infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Infection at pacemaker site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Arthroplasty revision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Sundowning/ICU &quot;psychosis&quot;</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack (TIA)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urinary tract infection (UTI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Chronic renal failure, or exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxia due to aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="14" subjects_affected="7" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Dyspnea/Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Respiratory failure, requiring intubation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Multiple lymphadenopathy (on chest CT)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery embolism of air, plaque, thrombosis, or debris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Slow flow or no reflow phenomena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Thrombosis formation at site of treated lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Coronary vessel dissection present</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Coronary vessel perforation present</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Non-coronary right ventricle vessel perforation present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Knee replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma at access site, requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hemorrhage, major, requiring transfusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Peripheral artery pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Peripheral artery/vascular disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="443"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="438"/>
              </event>
              <event>
                <sub_title>Cerebral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="443"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angiographic Complications</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="443"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="438"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any previously unpublished information provided to the Investigators by the Sponsor is confidential and will remain the sole property of the Sponsor. The Investigator agrees to use this information only in accomplishing this study not use it for other purposes without the Sponsor’s written consent. An Investigator can generate additional publication ideas based on the trial data. The Sponsor reserves the right to review the manuscript prior to submission in order to verify accuracy of the data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Cardiovascular Systems, Inc.</organization>
      <phone>6512591600</phone>
      <email>clinicaltrials_csi@csi360.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

